


Curriculum Vitae
Michael Whitler

Signature: 
Date Signed: 6/30/2008

Business Address:
CAMC Health Education and
Research Institute
Clinical Trials Center
3100 MacCorkle Avenue, SE
Suite 306
Charleston, WV 25304
Phone: (304) 388-9692
Fax: (304) 388-9935
Email: michael.whitler@camc.org

EDUCATION:

1999 – 2004 B.S. Sport and Exercise Psychology
 West Virginia University
 Morgantown, WV

1996 – 1999 Diploma
 Capital High School
 Charleston, WV

PROFESSIONAL EXPERIENCE:

2005 – Present Clinical Research Coordinator
 CAMC Health Education and Research Institute
 Charleston, WV

PROFESSIONAL AFFILIATIONS:

Association of Clinical Research Professionals

CERTIFICATIONS:

Basic Life Support – 2006
CITI – Course in The Protection of Human Research Subjects – 2005
Conducting Clinical Research Seminar – 2005
Phlebotomy Skills Training – 2005
Transportation of Dangerous Goods – 2005

CLINICAL RESEARCH EXPERIENCE:

4 Year of Research Experience to date

Clinical Research Coordinator: the primary role of the Research Coordinator is to screen and assess the patients in accordance with the protocol for eligibility, baseline, and follow-up procedures. The research coordinator is also responsible for assisting in the informed consent process, completing all case report forms, collecting the data, and maintaining documents and correspondence with the sponsor. The coordinator also completes all internal and external regulatory requirements.

HS# 08-06-2054: *DVT* - Protocol Title: Protocol B0661001 – CV185056: A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism, *Pfizer, Inc*

HS# 07-06-1992: *CENA* – A 48-week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon(R) 10 and 15cm² Patch in Patients with Alzheimer's Disease Showing Cognitive Decline During an Initial Open-Label Treatment Phase, *Novartis*

HS# 07-02-1907: *PEDS # 2 1-5 Extension* – An open label extension study to evaluate safety, tolerability, and efficacy of 18 weeks of valsartan treatment in children 1-5 years old with hypertension, *Novartis*

HS# 07-02-1908: *PEDS # 2 1-5* – A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 1-5 years old with hypertension, followed by a 2 week placebo withdrawal period, *Novartis*

HS# 07-02-1904: *PHOTOTHERA* - NeuroThera(R) Effectiveness and Safety Trial - 2 (NEST-2) A double blind, randomized, controlled, parallel group, multicenter, pivotal study to assess the safety and effectiveness of the treatment of acute ischemic stroke with the NeuroThera(R) Laser System within 24 hours from stroke onset, *PhotoThera®, Inc*

HS# 07-01-1894: *PEDS # 2 6-17 Extension* – Protocol Number CVAL489K2302 E01: A 14 week Extension to a randomized, double-blind, multicenter, parallel-group, active-controlled study to evaluate the long-term safety, tolerability and efficacy of valsartan and enalapril combined and alone in children 6 to 17 years of age with hypertension, *Novartis*

HS# 07-01-1893: *PEDS # 2 6-17* - Protocol Number CVAL489K2302: A multicenter, randomized, double-blind, parallel-group, evaluation of 12 weeks of valsartan compared to enalapril on sitting systolic blood pressure in children 6 to 17 years of age with hypertension, *Novartis*

HS# 07-01-1982: *PEARL* - Peripheral Use of AngioJet Rheolytic Thrombectomy with Mid-Length Catheters (PEARL Registry), *Possis Medical, Inc*

HS# 06-12-1885: *DAR 312* - DAR 312 Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension - A Phase 3 Randomized, Double-Blind, Placebo and Active Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Darusentan in

Subjects with Resistant Hypertension Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine or Placebo, *Myogen, Inc*

HS# 06-09-1851: *BeRite* - Benephit System Renal Infusion Therapy (BeRITe) Registry, *FlowMedica*

HS# 06-06-1828: *DAR-311E* - A Dose-Blinded, Long-Term Safety Extension Study of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Four or More Antihypertensive Drugs, Including Diuretic (DORADO EX), *Myogen, Inc*

HS# 06-06-1827: *DAR-311* - A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Four or More Antihypertensive Drugs, Including a Diuretic (DORADO), *Myogen, Inc*

HS# 06-03-1781: *ANCROD* - Protocol Number NTI-ASP-0503: ASP-II (Ancrod in Stroke Program-II): A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Vinprinx TM) in Subjects Beginning Treatment within 6 Hours of the Onset of Acute, Ischemic Stroke, *Neurobiological Technologies, Inc*

HS# 05-11-1742: *NABISH Hypothermia* - NABIS: H IIR: National Acute Brain Injury Study: Hypothermia II R, *National Institute of Health: National Institute of Neurological Disorders and Stroke (NINDS)*

HS# 05-11-1738: *RAD* - Protocol Number CRAD001A2309: A 24-Month, Multicenter, Randomized, Open-Label Non-Inferiority Study of Efficacy and Safety Comparing Concentration-Controlled Certican(R) in Two Doses (1.5 and 3.0mg/day starting doses) with Reduced Neoral(R) versus 1.44g Myfortic(R) with Standard Dose Neoral in De Novo Renal Transplant Recipients, *Novartis Pharmaceutical Corporation*

HS# 05-11-1737: *EXACT* - Protocol Number 640-0063-01: Emboshield (R) and Xact (R) Post Approval Carotid Stent Trial Using the Emboshield BarWire(TM) Rapid Exchange Embolic Protections System and Xact (R) Rapid Exchange Carotid Stent System: The EXACT Study, *Abbott Vascular, Inc*

HS# 04-03-1582: *PROPATEN* - Comparison of Primary Patency Between GORE-TEX(R) PROPATEN Vascular Grafts and Thin Walled GORE-TEX(R) Stretch Vascular Grafts, *W. L. Gore, & Associates, Inc*

HS# 04-01-1558: *PROFESS* - Prevention Regimen For Effectively Avoiding Second Strokes -- A Double-Blind, Active and Placebo Controlled Study of Aggrenox (R) Versus Clopidogrel, With and Without Micardis(R), *Boehringer Ingelheim Pharmaceuticals, Inc*

HS# 03-11-1538: *SAINT II* - Protocol Number SA-NXY-0007: A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke, *Astra Zeneca Pharmaceuticals*

HS# 03-06-1501: *OCARD* - OCARD Study - Obesity-Associated Cardiovascular Disease Susceptibility Genes, *Marshall University*

HS# 03-01-1439: *MAVERIC II* - Evaluation of the Medtronic AVE Self-Expanding Carotid Stent System with Distal Protection in the Treatment of Carotid Stenosis, *Medtronic AVE, Inc*

HS# 02-09-1407: *CREST* - Carotid Revascularization Endarterectomy vs. Stent Trial, *Advanced Cardiovascular Systems, Inc - Guidant Corporation*

HS# 02-05-1364: *MAVERIC* - Evaluation of The Medtronic AVE Self-Expanding Carotid Stent System With Distal Protection In The Treatment of Carotid Stenosis, *Medtronic Vascular*

HS# 01-12-1317: *SMART* - The Study of Percutaneous Transluminal Angioplasty with the SMART (TM) Self-Expanding Nitinol Vascular Stent for Obstructive Superficial Femoral Arteries and Randomized with ABCIXIMAB (Reopro) Administration, *Cordis, Inc*

HS# 01-11-1313: *DELIVER* - Protocol Number 01-345: Prospective, Randomized, Single-Blind, Parallel-Group (Two-Arm), Multi-Center, Clinical Evaluation of the RX ACHIEVE (TM) Drug-Coated Coronary Stent System in the Treatment of Patients with De Novo Native Coronary Artery Lesions, *Guidant Corporation*

HS# 01-01-1222: *SIRIUS* - Protocol Number P00-6302: A Multicenter, Randomized, Double-Blind Study of Sirolimus-Coated BX Velocity TM Balloon-Expandable Stent in the Treatment of Patients with De Novo Native Coronary Artery Disease Lesions,

+++ HS# is Internal study Identifier